Browse treatments

…m the immune system while inhibition of checkpoint signaling in cancer immunotherapy induces autoimmune-related adverse events. Two instructive cyto…

…ed analyses, enabling more confident peptide prioritization for cancer immunotherapy. By streamlining virtual screening, benchmarking, and peptide s…

…Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has represented…

…l stages creating a workflow for TCR analysis in the context of cancer immunotherapy: (1) data acquisition, including differences between TCR sequen…

…sion of tumor immunology research into a clinical discipline of cancer immunotherapy. As its second president (1986–1988), he led its growth and sci…

…Background Cancer immunotherapy has revolutionized treatment, offering new hope for patients wi…

…ponse in the myocardium and cytokine-mediated damage, requiring targeted therapy. Genetic pathogenic mutations in desmoplakin and other desmosom…

…3 received placebo, 403 received no treatment and 5735 received chemotherapy), while 10 076 patients were treated with ICI monotherapy.These…

…imulates T cell activation has renewed interest as a target for cancer immunotherapy. However, its clinical efficacy is still limited without approp…

… across diverse tumor types and represent promising targets for cancer immunotherapy. Clinical trials targeting these neoantigens have shown encoura…

…Background Cancer immunotherapy has evolved over decades into a frontline treatment for multipl…

…to destroy tumor cells, making them a promising cell source for cancer immunotherapy. However, solid tumors generate a unique microenvironment chara…